All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cancer location (esophagus) cancer location (gastric) cancer location (gastro-esophageal) cancer type (metastatic) ECOG 0 ECOG 1 Gender, female Gender, male metastasis (liver ) PD-L1 < 1% PD-L1 > 1% PDL1 (CPS >1) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) previous gastrectomy previous gastrectomy NO
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced mGC or mGEJC, anti-PD-(L)1 vs. Standard of Care (SoC), meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 649, 2021 0.80 [0.68; 0.94]
CheckMate 649 (PDL1 CPS>5), 2021 0.71 [0.59; 0.86]
JAVELIN Gastric 100, 2020 0.91 [0.74; 1.11]
JAVELIN Gastric 100 (PDL1>1%), 2020 1.13 [0.57; 2.24]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.91 [0.75; 1.11]
KEYNOTE-062 (P vs C ; CPS>10), 2020 0.69 [0.49; 0.97]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.85 [0.70; 1.03]
KEYNOTE-062 (PC vs C ; CPS>10), 2020 0.85 [0.62; 1.17]
0.82 [0.76 ; 0.89 ] CheckMate 649, 2021, CheckMate 649 (PDL1 CPS>5), 2021, JAVELIN Gastric 100, 2020, JAVELIN Gastric 100 (PDL1>1%), 2020, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (P vs C ; CPS>10), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>10), 2020 8 0% 4,473 moderate not evaluable progression or deaths (PFS)detailed results CheckMate 649, 2021 0.77 [0.68; 0.87]
CheckMate 649 (PDL1 CPS>5), 2021 0.68 [0.57; 0.82]
JAVELIN Gastric 100, 2020 1.04 [0.85; 1.28]
JAVELIN Gastric 100 (PDL1>1%), 2020 1.04 [0.53; 2.03]
KEYNOTE-062 (P vs C ; CPS>1), 2020 1.66 [1.37; 2.01]
KEYNOTE-062 (P vs C ; CPS>10), 2020 1.10 [0.80; 1.52]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.84 [0.70; 1.01]
KEYNOTE-062 (PC vs C ; CPS>10), 2020 0.73 [0.53; 1.00]
0.94 [0.75 ; 1.18 ] CheckMate 649, 2021, CheckMate 649 (PDL1 CPS>5), 2021, JAVELIN Gastric 100, 2020, JAVELIN Gastric 100 (PDL1>1%), 2020, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (P vs C ; CPS>10), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>10), 2020 8 88% 4,473 moderate not evaluable DCRdetailed results JAVELIN Gastric 100, 2020 0.62 [0.43; 0.89]
0.62 [0.43 ; 0.89 ] JAVELIN Gastric 100, 2020 1 0% 499 NA not evaluable objective responses (ORR)detailed results CheckMate 649, 2021 1.63 [1.30; 2.04]
CheckMate 649 (PDL1 CPS>5), 2021 1.80 [1.35; 2.39]
JAVELIN Gastric 100, 2020 0.91 [0.55; 1.51]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.29 [0.19; 0.45]
KEYNOTE-062 (P vs C ; CPS>10), 2020 0.55 [0.29; 1.04]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.60 [1.12; 2.28]
KEYNOTE-062 (PC vs C ; CPS>10), 2020 1.82 [1.02; 3.26]
1.05 [0.65 ; 1.70 ] CheckMate 649, 2021, CheckMate 649 (PDL1 CPS>5), 2021, JAVELIN Gastric 100, 2020, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (P vs C ; CPS>10), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>10), 2020 7 91% 3,864 moderate not evaluable AE (any grade)detailed results JAVELIN Gastric 100, 2020 1.25 [0.67; 2.33]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.34 [0.11; 1.06]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.68 [0.19; 2.43]
0.74 [0.33 ; 1.67 ] JAVELIN Gastric 100, 2020, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 51% 1,473 moderate not evaluable AE (grade 3-4)detailed results JAVELIN Gastric 100, 2020 0.98 [0.68; 1.40]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.09 [0.06; 0.14]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.16 [0.79; 1.71]
0.47 [0.10 ; 2.17 ] JAVELIN Gastric 100, 2020, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 98% 1,473 moderate not evaluable AE leading to death (grade 5)detailed results JAVELIN Gastric 100, 2020 1.22 [0.57; 2.59]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.19; 4.80]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.64 [0.39; 6.94]
1.24 [0.67 ; 2.31 ] JAVELIN Gastric 100, 2020, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 0% 1,473 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results JAVELIN Gastric 100, 2020 0.43 [0.28; 0.64]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.19 [0.09; 0.38]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.73 [1.13; 2.66]
0.53 [0.16 ; 1.78 ] JAVELIN Gastric 100, 2020, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 94% 1,473 moderate not evaluable SAE (any grade)detailed results JAVELIN Gastric 100, 2020 1.26 [0.86; 1.83]
1.26 [0.86 ; 1.83 ] JAVELIN Gastric 100, 2020 1 0% 481 NA not evaluable STRAE (any grade)detailed results CheckMate 649, 2021 1.98 [1.50; 2.61]
JAVELIN Gastric 100, 2020 0.79 [0.42; 1.50]
1.31 [0.54 ; 3.21 ] CheckMate 649, 2021, JAVELIN Gastric 100, 2020 2 85% 2,030 moderate not evaluable STRAE (grade 3-4)detailed results CheckMate 649, 2021 1.80 [1.33; 2.44]
1.80 [1.33 ; 2.44 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable TRAE (any grade)detailed results CheckMate 649, 2021 2.17 [1.49; 3.17]
JAVELIN Gastric 100, 2020 0.47 [0.31; 0.69]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.11 [0.06; 0.18]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.40 [0.70; 2.80]
0.62 [0.17 ; 2.32 ] CheckMate 649, 2021, JAVELIN Gastric 100, 2020, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 4 97% 3,022 moderate not evaluable TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.80 [1.47; 2.21]
JAVELIN Gastric 100, 2020 0.31 [0.19; 0.49]
0.75 [0.13 ; 4.28 ] CheckMate 649, 2021, JAVELIN Gastric 100, 2020 2 98% 2,030 moderate not evaluable TRAE leading to death (grade 5)detailed results CheckMate 649, 2021 7.88 [0.42; 149.34]
JAVELIN Gastric 100, 2020 0.49 [0.02; 14.64]
2.25 [0.15 ; 33.86 ] CheckMate 649, 2021, JAVELIN Gastric 100, 2020 2 32% 2,030 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 649, 2021 1.85 [1.48; 2.30]
JAVELIN Gastric 100, 2020 0.31 [0.18; 0.50]
0.76 [0.13 ; 4.44 ] CheckMate 649, 2021, JAVELIN Gastric 100, 2020 2 98% 2,030 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 649, 2021 2.12 [1.55; 2.90]
2.12 [1.55 ; 2.90 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.97 [0.06 ; 15.52 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 649, 2021 2.27 [1.34; 3.84]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.10 [0.03; 0.27]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.81 [0.48; 1.37]
0.61 [0.15 ; 2.53 ] CheckMate 649, 2021, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 93% 2,541 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 649, 2021 0.68 [0.26; 1.81]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.09 [0.01; 0.73]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.87 [0.35; 2.19]
0.55 [0.21 ; 1.42 ] CheckMate 649, 2021, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 48% 2,541 moderate not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.06; 15.44]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.49 [0.02; 14.58]
0.73 [0.09 ; 6.29 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.97 [0.06 ; 15.52 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.06 [0.49; 2.26]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.16 [0.05; 0.55]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.61 [0.28; 1.34]
0.53 [0.21 ; 1.34 ] CheckMate 649, 2021, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 69% 2,541 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.45 [0.85; 2.46]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.20 [0.06; 0.69]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.83 [0.38; 1.83]
0.71 [0.27 ; 1.90 ] CheckMate 649, 2021, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 77% 2,541 moderate not evaluable Dizziness TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.48 [0.02; 14.35]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.06; 15.69]
0.73 [0.09 ; 6.31 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 low not evaluable Dry skin TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.97 [0.06 ; 15.52 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable Dysgeusia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.97 [0.06 ; 15.52 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 649, 2021 9.86 [0.54; 180.88]
9.86 [0.54 ; 180.88 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.76 [0.96; 3.22]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.06 [0.01; 0.50]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.35 [0.66; 2.76]
0.85 [0.27 ; 2.66 ] CheckMate 649, 2021, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 78% 2,541 moderate not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 649, 2021 1.73 [1.04; 2.86]
1.73 [1.04 ; 2.86 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 649, 2021 1.81 [0.97; 3.36]
1.81 [0.97 ; 3.36 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 1.92 [0.06; 57.64]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.96 [0.07; 58.57]
1.94 [0.18 ; 21.47 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 649, 2021 2.38 [0.83; 6.77]
2.38 [0.83 ; 6.77 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.18 [0.36; 3.88]
1.18 [0.36 ; 3.88 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 649, 2021 2.87 [1.61; 5.12]
2.87 [1.61 ; 5.12 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.48 [0.02; 14.35]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 5.98 [0.71; 50.01]
2.43 [0.23 ; 25.98 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 34% 992 low not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.03 [0.00; 0.51]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.70 [0.32; 1.56]
0.20 [0.01 ; 4.07 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 77% 992 low not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.03 [0.55; 1.95]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.05 [0.01; 0.37]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.03 [0.53; 2.02]
0.60 [0.21 ; 1.75 ] CheckMate 649, 2021, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 76% 2,541 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.29 [0.96; 1.72]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.01 [0.00; 0.08]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.87 [0.58; 1.30]
0.66 [0.26 ; 1.66 ] CheckMate 649, 2021, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 88% 2,541 moderate not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.81 [0.67; 4.92]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.06 [0.00; 1.02]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.49 [0.60; 3.70]
1.04 [0.32 ; 3.44 ] CheckMate 649, 2021, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 60% 2,541 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.40 [0.80; 2.44]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.24 [0.01; 5.32]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.97 [0.36; 10.84]
1.37 [0.82 ; 2.31 ] CheckMate 649, 2021, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 0% 2,541 moderate not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.12 [0.54; 2.32]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 5.91 [0.29; 118.71]
1.33 [0.50 ; 3.53 ] CheckMate 649, 2021, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 10% 2,043 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.97 [0.06 ; 15.52 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 moderate not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.96 [0.02; 48.60]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.96 [0.07; 58.57]
1.44 [0.11 ; 18.83 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 low not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 649, 2021 5.92 [0.71; 49.31]
5.92 [0.71 ; 49.31 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 649, 2021 13.96 [1.83; 106.45]
13.96 [1.83 ; 106.45 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 649, 2021 4.36 [1.79; 10.66]
4.36 [1.79 ; 10.66 ] CheckMate 649, 2021 1 0% 1,549 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.05 [0.00; 0.89]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.20 [0.49; 2.95]
0.34 [0.02 ; 6.97 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 77% 992 low not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 649, 2021 1.44 [0.71; 2.95]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.08 [0.00; 1.41]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.14 [0.38; 3.45]
1.00 [0.38 ; 2.62 ] CheckMate 649, 2021, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 46% 2,541 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 649, 2021 0.69 [0.37; 1.29]
KEYNOTE-062 (P vs C ; CPS>1), 2020 0.03 [0.00; 0.55]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.83 [0.38; 1.83]
0.57 [0.23 ; 1.40 ] CheckMate 649, 2021, KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 3 57% 2,541 moderate not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-062 (P vs C ; CPS>1), 2020 0.48 [0.02; 14.35]
KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.96 [0.18; 21.75]
1.22 [0.17 ; 8.73 ] KEYNOTE-062 (P vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>1), 2020 2 0% 992 low not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-06 13:49 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 273,122,271,262,260,219,184,272,123,187,185,186,304
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563